Technology & autonomy · Jakarta, Indonesia
DeepVertex is a technology company from Jakarta. We build autonomous systems that take over the dangerous, repetitive parts of the job — keeping people safe and operations moving.
Soon available on
App Store
Google Play
Windows
Ubuntu
macOS
Our mascot
Named for the dawn — and for ora, the old Indonesian name of the Komodo dragon. In the Ata Modo legend, the dragon is a sibling of humans, never an enemy; we build in that spirit.
Zora rides with the fleet. The light along its body is the light we carry into the deep — and bring back with the data.
See the fleet
What we do
When a job is dangerous, too hard, or simply repetitive, it deserves better tools. We build them, prove them, and stand behind the numbers — that’s how work gets safer, and how industries move.
The divisions
Water, air, ground and health. Different domains, one discipline — autonomy that proves itself in the hardest conditions first.
Map and inspect what divers can’t — safer, faster, at a fraction of the cost.
Active 02Delivery, mapping and disaster response — for the places roads never reach.
Coming soon 03Inspection, logistics and hazardous-site work — the heavy, risky jobs, handled.
Coming soon 04Patient monitoring for clinical teams.
In developmentFlagship program — Marine Technology
Marine Technology →A stereo pair and the vehicle’s own IMU replace a full survey-grade positioning kit — 20 Hz pose, under 0.5 % error in simulation, for about US$280 in hardware. Coral restoration is the first proving ground; shipwrecks, pipelines and underwater infrastructure use the same mission.
Cost comparison — vendor list prices, 2026
31× less hardware — same 20 Hz pose stream, under 0.5 % error in simulation.
Numbers from the project deck: simulation results; stereo hardware vs survey-grade DVL (vendor list prices, 2026).
Why we exist
Our aim is to move the country from distributor and consumer to innovator and developer. Research comes first — with government, industry and local communities.
Healthcare Technology
In development with early clinical partners.
